Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

On the other hand, a non-significant trend towards increased PTH levels (Table 3 and Fig. 3B) and unaltered phosphate and vitamin D levels were observed (Fig. 3C and D).

Source: Genotype-dependent alteration of parathyroid hormone levels. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Participants were classified as symptomatic if they exhibited at least one of the following signs or symptoms that could not be attributed to a competing illness, based on the criteria adapted from Manyam et al.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcification

Study design awaiting verification · Brain Communications · 2025

Original publication title

Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcification

Janine Schwahn; Sophie Hebestreit; Olivia Kosche; Petra Steinacker; Vesile Sandikci; Isabel Winzer; Jasper Hesebeck-Brinckmann; Franziska Bachhuber; Ivan Valkadinov; Stefanie Nittka; Lukas Mesin; Max Brauner; Christine von Arnim; Nandhini Santhanam; Marvin Spreyer; Robert Sackmaier; Antje Knehr; Paula Barthel; Oliver Bähr; Herbert Gruber; Sabine Stallforth; Martin Regensburger; Jürgen Winkler; Rüstem Yilmaz; Michael Neumaier; Hayrettin Tumani; Mate E Maros; Holger Wenz; David Brenner; Markus Otto; Anne Ebert; Julian Conrad; Jochen H Weishaupt

© The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Abstract

Primary brain calcification (primary familial brain calcification in inherited cases) is an often-genetic condition characterized by symmetrical brain calcifications and neuropsychiatric symptoms. The calcifications can also occur without overt clinical symptoms. Identifying laboratory biomarkers in primary brain calcification and their association with imaging, genetic, and clinical data will be crucial for a deeper understanding of primary brain calcification causation and progression and the planning of therapeutic trials. The serum biomarkers for neuronal degeneration (phosphorylated tau, neuron-specific enolase, neurofilament light: and heavy chain) and glial activation (glial fibrillary acidic protein, S100 calcium-binding protein B) were measured in 101 probands (41 controls and 60 probands with primary brain calcification).

The deep phenotyping protocol of the German Fahr-NET register included neurological and neuropsychological examination, routine laboratory workup, and whole exome sequencing. We also performed and analyzed 45 cranial CT scans using the total calcification score. While mild pallidal calcifications were observed early in young, asymptomatic primary brain calcification mutation carriers, individuals with calcifications extending beyond the pallidum were symptomatic. Individuals with primary brain calcification had elevated serum glial fibrillary acidic protein and neurofilament light chain levels. Serum biomarkers correlated with both the extent of calcifications and the clinical impairment.

Elevated parathyroid hormone levels distinguished the primary brain calcification group without identified mutation from both genetic primary brain calcification and control groups. Our results define a practical imaging cut-off indicating the presence of primary brain calcification symptoms. Elevated parathyroid hormone levels in primary brain calcification without identified mutation, but not in primary brain calcification with a monogenic cause, suggest abortive calcium regulation defects as a pathogenic factor specifically for primary brain calcification without identified mutation. Elevated glial fibrillary acidic protein and neurofilament concentrations in individuals with primary brain calcification indicate early, chronic astrocytosis and neuronal impairment, respectively.

The significant association of neurofilament light chain with clinical scores and brain imaging results will be relevant for future therapeutic studies.

Schwahn et al. report that individuals with primary brain calcification had elevated serum glial fibrillary acidic protein and neurofilament light chain levels indicating early, chronic astrocytosis and neuronal impairment. The significant association of neurofilament light chain with clinical scores and brain imaging results will be relevant for future therapeutic studies.

Authors’ abstract

Abstract

Primary brain calcification (primary familial brain calcification in inherited cases) is an often-genetic condition characterized by symmetrical brain calcifications and neuropsychiatric symptoms. The calcifications can also occur without overt clinical symptoms. Identifying laboratory biomarkers in primary brain calcification and their association with imaging, genetic, and clinical data will be crucial for a deeper understanding of primary brain calcification causation and progression and the planning of therapeutic trials. The serum biomarkers for neuronal degeneration (phosphorylated tau, neuron-specific enolase, neurofilament light: and heavy chain) and glial activation (glial fibrillary acidic protein, S100 calcium-binding protein B) were measured in 101 probands (41 controls and 60 probands with primary brain calcification).

The deep phenotyping protocol of the German Fahr-NET register included neurological and neuropsychological examination, routine laboratory workup, and whole exome sequencing. We also performed and analyzed 45 cranial CT scans using the total calcification score. While mild pallidal calcifications were observed early in young, asymptomatic primary brain calcification mutation carriers, individuals with calcifications extending beyond the pallidum were symptomatic. Individuals with primary brain calcification had elevated serum glial fibrillary acidic protein and neurofilament light chain levels. Serum biomarkers correlated with both the extent of calcifications and the clinical impairment.

Elevated parathyroid hormone levels distinguished the primary brain calcification group without identified mutation from both genetic primary brain calcification and control groups. Our results define a practical imaging cut-off indicating the presence of primary brain calcification symptoms. Elevated parathyroid hormone levels in primary brain calcification without identified mutation, but not in primary brain calcification with a monogenic cause, suggest abortive calcium regulation defects as a pathogenic factor specifically for primary brain calcification without identified mutation. Elevated glial fibrillary acidic protein and neurofilament concentrations in individuals with primary brain calcification indicate early, chronic astrocytosis and neuronal impairment, respectively.

The significant association of neurofilament light chain with clinical scores and brain imaging results will be relevant for future therapeutic studies.

Schwahn et al. report that individuals with primary brain calcification had elevated serum glial fibrillary acidic protein and neurofilament light chain levels indicating early, chronic astrocytosis and neuronal impairment. The significant association of neurofilament light chain with clinical scores and brain imaging results will be relevant for future therapeutic studies.

Publication and source details

Original title: Deep clinical, genetic, and serum biomarker profiling indicates glial and neuronal pathology in primary brain calcification

Janine Schwahn; Sophie Hebestreit; Olivia Kosche; Petra Steinacker; Vesile Sandikci; Isabel Winzer; Jasper Hesebeck-Brinckmann; Franziska Bachhuber; Ivan Valkadinov; Stefanie Nittka; Lukas Mesin; Max Brauner; Christine von Arnim; Nandhini Santhanam; Marvin Spreyer; Robert Sackmaier; Antje Knehr; Paula Barthel; Oliver Bähr; Herbert Gruber; Sabine Stallforth; Martin Regensburger; Jürgen Winkler; Rüstem Yilmaz; Michael Neumaier; Hayrettin Tumani; Mate E Maros; Holger Wenz; David Brenner; Markus Otto; Anne Ebert; Julian Conrad; Jochen H Weishaupt

Brain Communications · 2025

Correspondence to: Prof. Dr. med. Jochen Weishaupt Department of Neurology, Ulm University, Oberer Eselsberg 45, Ulm 89081, Baden-Württemberg, Germany E-mail: jochen.weishaupt@uni-ulm.de© The Author(s) 2025. Published by Oxford University Press on behalf of the Guarantors of Brain.2025https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. Dr. Rolf M. Schwiete Foundation10.13039/501100020027 # 2021 to 042

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T02:33:18.623654+00:00

DOI: 10.1093/braincomms/fcaf388 · PMC12574706